

Treatment Naïve, Chronic HCV

Peginterferon alfa -2a+/- Ribavirin
versus
Interferon alfa-2b + Ribavirin


Fried MW, et al. N Engl J Med. 2002;347:975-82.

Peginterferon +/- Ribavirin versus Interferon + Ribavirin Study Features

- **Study**
 - Open-label randomized controlled trial
- **Subjects**
 - N = 1149 with chronic hepatitis C randomized
 - Treatment naïve; 62% genotype 1
 - Serum ALT above upper limit of normal x prior 6 months
- **Regimens (48 Week Treatment)**
 - Peginterferon alfa-2a 180 µg 1x/week + Ribavirin 1000-1200 mg/day
 - Peginterferon alfa-2a 180 µg 1x/week + Placebo
 - Interferon alfa-2b 3 million U 3x/week + Ribavirin 1000-1200 mg/day
- **Primary Endpoint**
 - Undetectable serum HCV RNA 24 weeks after stopping treatment

*Ribavirin dosing: <75 kg: 1000 mg/day; ≥75 kg: 1200 mg/day

Peginterferon +/- Ribavirin versus Interferon + Ribavirin Study Design



Drug Dosing


Peginterferon alfa-2a 180 µg 1x/week

Weight-based Ribavirin (divided bid): 1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg

Interferon alfa-2b 3 million U 3x/week

Peginterferon +/- Ribavirin versus Interferon + Ribavirin Results

Virologic Responses, by Treatment Regimen



Peginterferon +/- Ribavirin versus Interferon + Ribavirin Conclusions

Conclusions: “In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.